GB201704267D0 - Novel biomarker - Google Patents

Novel biomarker

Info

Publication number
GB201704267D0
GB201704267D0 GBGB1704267.2A GB201704267A GB201704267D0 GB 201704267 D0 GB201704267 D0 GB 201704267D0 GB 201704267 A GB201704267 A GB 201704267A GB 201704267 D0 GB201704267 D0 GB 201704267D0
Authority
GB
United Kingdom
Prior art keywords
novel biomarker
biomarker
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1704267.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genome Research Ltd
Stichting Het Nederlands Kanker Instituut
Original Assignee
Genome Research Ltd
Stichting Het Nederlands Kanker Instituut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genome Research Ltd, Stichting Het Nederlands Kanker Instituut filed Critical Genome Research Ltd
Priority to GBGB1704267.2A priority Critical patent/GB201704267D0/en
Publication of GB201704267D0 publication Critical patent/GB201704267D0/en
Priority to PCT/GB2018/050701 priority patent/WO2018167519A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/91245—Nucleotidyltransferases (2.7.7)
    • G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
GBGB1704267.2A 2017-03-17 2017-03-17 Novel biomarker Ceased GB201704267D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1704267.2A GB201704267D0 (en) 2017-03-17 2017-03-17 Novel biomarker
PCT/GB2018/050701 WO2018167519A1 (en) 2017-03-17 2018-03-16 Biomarker for identifying responders to cancer treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1704267.2A GB201704267D0 (en) 2017-03-17 2017-03-17 Novel biomarker

Publications (1)

Publication Number Publication Date
GB201704267D0 true GB201704267D0 (en) 2017-05-03

Family

ID=58688406

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1704267.2A Ceased GB201704267D0 (en) 2017-03-17 2017-03-17 Novel biomarker

Country Status (2)

Country Link
GB (1) GB201704267D0 (en)
WO (1) WO2018167519A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201938165A (en) * 2017-12-18 2019-10-01 美商輝瑞股份有限公司 Methods and combination therapy to treat cancer
CN113046357B (en) * 2021-01-25 2023-05-16 柳州市柳铁中心医院 Levalatinib drug-resistant gene DUSP9, screening method and application thereof
US11945785B2 (en) 2021-12-30 2024-04-02 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of FLT3
CN117431323A (en) * 2023-12-20 2024-01-23 广州嘉检医学检测有限公司 NF1 gene detection reagent and detection method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015156674A2 (en) * 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
US10028958B2 (en) * 2014-04-19 2018-07-24 Massachusetts Institute Of Technology Methods of treating cancer with a combination of selected MEK1/2 and AXL inhibitors

Also Published As

Publication number Publication date
WO2018167519A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
GB2566681B (en) Biomarker
SG10202007262PA (en) Copanlisib biomarkers
SG10202007322PA (en) Copanlisib biomarkers
GB201614455D0 (en) Biomarkers
GB201719639D0 (en) Setection of biomarkers
ZA202001821B (en) Biomarker
GB201703058D0 (en) Biomarkers
GB201404189D0 (en) Novel biomarkers
GB201710858D0 (en) Biomarker
GB201704267D0 (en) Novel biomarker
GB201804648D0 (en) Combination biomarker
GB201500729D0 (en) Novel Biomarkers
GB201703123D0 (en) Biomarkers
GB201811093D0 (en) Biomarker
GB201512133D0 (en) Biomarkers
IL268770A (en) Aptamer as biomarkers
GB201720776D0 (en) Biomarkers
GB201707113D0 (en) Biomarker
GB201807367D0 (en) Biomarker
GB201706669D0 (en) Biomarkers
GB201702986D0 (en) Biomarkers
GB201808489D0 (en) Novel biomarkers
GB201808400D0 (en) Novel biomarkers
GB201809869D0 (en) Biomarkers
GB201809868D0 (en) Biomarkers

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)